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ABSTRACT 
 
OBJECTIVE:  The objective of this selective EBM review is to determine whether or not 
vitamin D supplement is effective in improving physical performance in older patients with heart 
failure over the age 50 years 
STUDY DESIGN:  Review of three English language primary studies, two published in 2010 
and one was published in 2013. 
DATA SOURCES:  Two double blind randomized controlled trials (RCT) and one cross-
sectional study that investigated the use of vitamin D in improving physical performance in heart 
failure. Sources were selected and found using PubMed, ScienceDirect, and Cochrane databases. 
OUTCOMES MEASURED:  The outcomes measured were improvement of physical 
performance, and associations among muscle strength, health status measures, and serum vitamin 
D.  Tools used to measure were, a 6 minute walk distance test (6MWD), timed get up and go test 
(TGUG), isokinetic muscle testing. 
RESULTS:  The results of two RCT studies Boxer et al. (2013) and Witham et al. (2013) 
supported that vitamin D does not improve physical performance. The Boxer et al. (2010) cross-
sectional study showed no association among serum vitamin D concentration, muscle strength, 
and health status. Boxer et al. (2013) and Witham et al. (2013) demonstrated that the 6MWD test 
and TGUG test did not improve with physical activity.  
CONCLUSION:  The results of the RCT’s and the cross-sectional study reviewed; suggest that 
Vitamin D does not improve the physical performance of older adults with heart failure. This 
topic does warrant additional research. Further studies conducted should include more frequent, 
lower doses of vitamin D and examine the results for a longer period of time. The effects of sun-
exposure on vitamin D concentration and improvement of physical activity also should be 
investigated. 
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INTRODUCTION 
 Heart failure is identified as an abnormality in heart structure or function leading to 
inability of the heart to pump blood at an output sufficient to meet requirements of metabolizing 
tissues or the ability to do so at abnormally elevated diastolic pressures/volume.
1
 Average age of 
patients with heart failure is 76 years in the United Kingdom, with 10% of populations aged ≥ 80 
years have heart failure.
2
  The incidence of heart failure increases fourfold between the ages of 
65 and 85 years .
3
 Heart failure is currently the most common cause of hospitalization in the 
persons in the Medicare age group; more than 70% of the nearly 1 million annual 
hospitalizations for heart failure involve persons older than 65 years of age.
 3
 Between 1 and 2% 
of the total health care budget in many developed countries is spent on hospitalizations resulting 
from heart failure. In 2009, the total cost of heart failure was estimated to be $37.2 billion in the 
United States.
4
  
 Decline in physical function and poor quality of life remains main characteristics of the 
patients with heart failure. Currently management of patients with heart failure is limited to 
pharmacology therapy and diet plans to prevent the progression of the disease.
1
 Patients with 
NYHA Class I-III heart failure have benefitted from regular, mild exercises, such as walking or 
using stationary-bicycles.
1
 Despite the therapies available to patients with heart failure, physical 
functioning remains poor in older adults with heart failure.  Several studies; including Boxer et 
al. (2008) have demonstrated that vitamin D deficiency is associated with reduced physical 
performance and frailty.
5
 Repletion of vitamin D has shown to result in improvement in strength 
and balance and reduced risk of falls.
6
  Evidence shows that vitamin D also down-regulates the 
renin-angiotensin system (RAAS)
7
  and reduces blood pressure,
7
 which both can be of particular 
importance in patients with heart failure according to the  hypothesis that dysregulation of 
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neurohormanal pathways leads to muscle myopathy.
6
 Heart failure and vitamin D deficiency are 
both common in older adults.
8
 Therefore, vitamin D supplementation could improve the physical 
performance in older individuals with heart failure. 
OBJECTIVE 
 The objective of this selective EBM review is to determine whether or not “vitamin D 
supplementation is effective in improving physical performance in older patients with heart 
failure who are over the age of 50 years.” 
METHODS 
 The selected articles included men and women with heart failure who were older than 50 
years of age. The intervention chosen in the two RCT’s was oral vitamin D compared to a 
placebo. The cross-sectional study examined the association among serum vitamin D, muscle 
strength and health status. The outcomes addressed included improvement of physical 
performance, on 6 minute walk distance test (6MWD) and timed get up and go (TGUG). 
Associations among serum vitamin D concentration, muscle strength, and health status were 
studied in cross sectional study by measuring vitamin D levels and muscle strength. The types of 
studies included were two RCTs, and one cross-sectional study.  
 Key words vitamin D, heart failure and physical performance were searched using the 
following search engines: PubMed, ScienceDirect, and Cochrane Database. Articles selected 
were written in the English language, peer reviewed, and published between 2010 and 2013 and 
had not been previously used in a systematic review or meta-analysis. Inclusion criteria for these 
studies were RCTs that were published in 2000 or later based on their relevance and importance 
of the outcome to the patient (Patient Oriented Evidence That Matters, POEMS) and that 
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investigated the effectiveness of vitamin D in improving physical performance in patients with 
heart failure (Table 1). Exclusion criteria consisted of studies that investigated patients younger 
than age 50 years, without a diagnosis of heart failure, patients who were taking daily vitamin D 
supplements, and patients with a diagnosis of osteoporosis (Table 1). Statistics were reported 
using mean±SD change from baseline, linear regression model, ANCOVA, Pearson X2, Pearson 
product moment correlation, and p-value 
OUTCOMES MEASURED 
 The outcomes were measured via several different methods. Boxer et al. (2013) measured 
physical performance at base line and 6 months with the TGUG and 6MWD. TGUG is a reliable 
and valid test of basic mobility maneuvers, including balance, gait, speed, strength, and 
functional ability used in measuring clinically significant changes in mobility in older frail 
patients.
2
 6MWD has been validated for patients with heart failure; it reflects the type of aerobic 
activity that older persons with health failure undertake.
2
 Both of these tests are globally used in 
older individuals to measure basic mobility. They closely mirror the type of aerobic activity that 
older persons with health failure undertake. Witham et al. (2013) measured physical performance 
using TGUG and 6MWD. To measure muscle strength, Boxer et al. (2010) used Biodex System 
3 Pro Isokinetic Dynamometer. Health status was assessed the by Kansas City Cardiomyopathy 
Questioner, a 23-item self-administered instrument. Serum analysis was performed by collecting 
blood, and measuring vitamin D levels by Chemiluminescent Immunoassay. 
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Table 1 - Demographics & Characteristics of Included Studies 
Study Type  # 
Pts 
Age Inclusion  
criteria 
Exclusion  
criteria 
W/D intervention 
Boxer 
(2010) 
Cross  
sectional 
40 67.8 
±10.9 
years  
Patients’ age 
≥50 with 
either systolic 
or preserved 
systolic 
function HF. 
25OHD 
concentration 
b37.5 ng/mL 
primary 
hyperparathyroi
dism or 
hypercalcemia; 
nephrolithiasis; 
diagnosis of 
osteoporosis; 
hemodialysis or 
peritoneal 
dialysis and/or 
creatinine of 
N2.5 mg/dL; 
current use of 
daily vitamin D 
N400 IU, 
corticosteroids, 
PTH, androgen, 
estrogen 
 0 Association 
among 
Serum 
25OHD 
(vitamin D) 
and muscle 
strength  
 
Boxer 
(2013) 
Double 
Blind 
RCT 
64 65.9  
±10.4 
years 
Patients age ≥ 
50, with HF in 
class II to IV. 
Receiving 
maximum 
doses of 
evidence-
based HF 
medication. 
The required 
serum 25 
(OH)D level 
≤37.5ng/ml. 
Primary 
hyperparathyroi
dism, sarcoid, 
hypercalcemia, 
nephrolithiasis, 
osteoporosis, 
creatinine >2.5 
mg/dl,  
vitamin D 
supplementatio
n >400 IU/day 
10 –
W/D 
 
2- 
Diseased 
 
64-
included 
in 
analysis 
vitamin D3 
50,000 IU 
daily for 6 
months 
Witham 
(2010) 
Double 
Blind 
RCT 
105 aged 
≥70 
years 
aged ≥ 70 
years with 
diagnosed 
chronic heart 
failure and 
25-
hydroxyvitam
in D level of < 
50 nmol/L 
clinical 
diagnosis of 
osteomalacia, 
under 
investigation for 
recurrent falls, 
already taking 
vitamin D 
supplements, 
moderate to 
severe cognitive 
impairment 
6 due to 
death 
 
1 ill 
health 
 
2 other 
reasons 
 
105-
included 
in 
analysis 
100,000 U 
of oral 
vitamin D2 
at baseline, 
10 weeks, 
and 20 
weeks 
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RESULTS 
 The three articles presented in this review had continuous data, which could not be 
converted to dichotomous data. In the study done by Boxter et al. (2013), the reported statistics 
compared oral vitamin D supplement to placebo. The results of the TGUG and 6MWD, were 
calculated for vitamin D (n=31) group, and placebo group (n=33) as mean ±SD, at baseline and 6 
months (Table 2).  The treatment effect, (vitamin D versus placebo) was evaluated at each end 
point by ANCOVA model as frequencies and proportions for categorical variables within study 
groups. In TGUG and 6MWD, the differences in physical function improvement between the 
vitamin D group and placebo group were 0.8 and 20, respectively.
6
 The results did not reach a 
statistically significant value, p=0.30
6
 (TGUG) and p=0.80
6
 (6MWD) (Table 2).  
Table 2 - Change in Aerobic Capacity and Muscle Strength in the vitamin D and Placebo Groups 
                                    6-Month change in endpoint                                 ANCOVA model 
 
                                                                                                       Vitamin D – Placebo          
  End point             Vitamin D (=31)            Placebo (n=33)                  Difference                     p value                             
TGUG  
baseline to 6 mo 
-.02  ± 3.3 -1.0  ± 3.3 0.8 0.30 
6MWD (m)  
Baseline to 6 mo 
59  ±  282 36  ± 228 20 0.80 
Values are mean ± SD. ANCOVA= analysis of covariance 
 In the study performed by Witham et al. (2013) statistics reported; compared vitamin D 
supplement to placebo. Differences between groups were compared at baseline versus 10 weeks, 
and base line versus 20 weeks. Pearson X
2
 test was used to compare categorical variables. Of the 
participants in the placebo group (n=52), 46 (88%) completed 6MWD test at the end of week 
10
th
, compared with 45 (85%) in the treatment group (n=53). In the 6MWT, a change of 30 m in 
distance is the minimum required to show clinical improvements.
2
 The between group difference 
at baseline versus 10 weeks showed no significant improvement. -2.4 (95% confidence interval 
[CI], -17.1 to 12.4); (p=0.75).
 2
 (Table 3). At 20 weeks, 42 participants in each group (81% in 
 Yazdani, Vitamin D for HF 6 
 
placebo and 79% in vitamin D group) were able to complete the 6MWD. Unadjusted analysis 
(Table 3) and adjusted analysis (for key variables at baseline) showed no improvement with 
vitamin D supplementation p=0.51
2
 in unadjusted analysis (Table3) and p=0.68
2
 in adjusted 
analysis. Also outcomes on TGUG showed no improvement with vitamin D supplementation
2
 
(Table 3).  The score of TGUG at 10 weeks and 20 weeks showed no significant improvement in 
function either. At week 10, the between group difference was 0.21 (CI -1.79 to 1.37); (p= 0.80), 
and at 20 weeks, the between group difference was 1.42 (CI -1.13 to 3.97); (p=.27); (Table 3).
 2
  
Table 3- Changes in Outcome Measures 
                                            0 VS. 10 weeks                                           0 VS. 20 weeks 
 
                               Between- group                                             Between- group  
                                 Difference (95% CI)                  p                   Different (95% CI)                 p                                         
6-min, m -2.4(-17.1 to 12.4) 0.75 -5.6(-22.2 to 11.0) 0.51 
TGUG, s 0.21(-1.79 to 1.37) 0.80 1.42(-1.13 to 3.97) 0.27 
 
 In the last study, Boxer et al. (2010) assessed the association among serum vitamin D 
concentrations (a level of ≤0.05 was considered significant), physical performance, and health 
status. A linear regression model then studied the association after adjusting for other potential 
variables.
7
 The mean serum vitamin D concentration was 18.5 ± 9.1 ng/m.
7
 The levels varied by 
race, with African Americans having the lowest  (16 versus  22 ng/ml, p=0.4). Muscle strength 
was measured by weight bearing ability in flexion, with men having a mean (n=18) of 17.1 ± 6.7, 
and women (n=21) of 16.1 ± 6.1.
 7
 There was no association between serum vitamin D 
concentration and muscle streghth.
7 
Data showed, “Older age trended toward significance at 
p=0.08,
 with older age relating to lower peak torque.” 7 The mean total score on Kansas City 
Cardiomyopathy Questionnaire (KCCQ) was 68.9 ± 22.9.
7
 There was also no association 
between KCCQ total score and serum vitamin D concentrations. However, there was an 
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association between serum vitamin D levels and physical limitation scores, which is one of the 
four domains of KCCQ (r=0.32, and p= 0.04)
7
. However, after data were adjusted for African 
Americans (with lowest score) and New York Heart Association (NYHA), (lower class of heart 
failure had highest score), the association was lost.
7
  
 In the two RCT’s, control groups were vitamin D groups. However, in the cross-sectional 
study there was no control group, and association between three variables was studied. Each 
study had specific inclusion/exclusion criteria. They all included patients in NYHA functional 
Class II to IV who were 50 years of age or older. Boxer et al. (2010) and Boxer et al. (2013) 
excluded patients who were taking daily vitamin D supplements of > 400 IU and with a 
diagnosis of osteoporosis. Witham et al. (2013) excluded any patient who was taking any daily 
dose of vitamin D and those with a current diagnosis of osteopenia. 
 In Boxer et al. (2013) study, six patients from the control group and six patients from the 
placebo group did not complete the trial.
6
 One patient in each group died and five in each group 
withdrew.
6
 The monthly pill counts showed 100% compliance in the vitamin D group and 99.5% 
in the placebo group.
6
 Witham et al. (2013) reported, the death of two patients in each group 
before completion of Week 10, and another two deaths in control group before Week 20. One 
individual dropped of the control group because of ill health before Week 20. One patient in the 
placebo group violated the protocols and was dropped between Week 10 and 20 and one other 
patient in the placebo group moved away between Week 10 and 20 and thus dropped out.
1
 To 
ensure adherence, a research nurse  directly observed each patient take the pill in the 
participant’s own home.1 Adherence was reported 100% throughout.”1   
 Yazdani, Vitamin D for HF 8 
 
 Both the Boxer et al. (2013) and Witham et al. (2013) studies showed interventions were 
well tolerated.
2, 6 
Boxer et al. reported no significant difference between the control group and 
the placebo group with the exception of increasing numbers of infections in the vitamin D group 
(18 compared to six).
6
 Witham et al. (2013) reported an increase of creatinine of greater than 
25% in five patients in the vitamin D group compared to one patient in the placebo group 
(p=0.11).
2 
DISCUSSION 
 The results from Boxer et al. (2013) and Witham et al. (2013) studies, showed physical 
performance in older patients with heart failure did not improve by vitamin D supplementation.
2,6
 
Boxer et al. (2010) found no association between the serum vitamin D concentrations and muscle 
strength.
7 
The studies performed contained some factors that may have affected the outcome 
results. Boxer et al. (2013) used a diverse study population with strong presentation of women.
6
 
Witham et al. (2013) study included a large sample size however, it underrepresented women.
7
 
On the other hand, Witham et al. states “30 m is the minimum clinically important 
improvement”2 6MWT. Also the subsequent narrow CI around the 6MWT “makes it unlikely 
that any clinically significant effect were missed in Witham study.”2 Such result is in agreement 
with the findings of studies investigated in this paper. 
 Result from the study of vitamin D effects in older individuals without a diagnosis of 
heart failure with vitamin D insufficiency, showed some benefits in physical performance after 
treatment with vitamin D.
8
 Small and frequent dose of 800 to 1000 IU/day of vitamin D, and 
specifically combined with calcium has shown benefits in the results of TGUG but not 6MWD.
7 
Boxer et al. (2013) study used high dose of vitamin D3 with calcium as intervention. It is 
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possible that a smaller, more frequent dose of vitamin D3 might be beneficial in improvement of 
physical performance in older patients with heart failure. Witham et al. (2013) did not use any 
calcium with the vitamin D administration.
2
 
 Outcomes in the Boxer et al. (2013) and Witham et al. (2013) studies could be different if 
therapy was continued for a longer period of time. A longer duration therapy with the vitamin D 
could elicit changes in physical function.
2, 6
  Boxer et al. (2010) study was limited by cross-
sectional design due to the fact that it only studied association between variables. Sample sizes in 
Boxer et al. (2013) and Boxer et al. (2010) were too small.
6, 7
 A larger sample size could lead to 
different outcomes in both studies. Boxer et al. (2013) explains that it is theorized vitamin D 
reduces the risk for infection and inflammations,
6
 however the most significant adverse event in 
this study  was  the higher number of infections in vitamin D group compared to the placebo 
group,
6
 “This might be due to small sample size or to multiple comparisons.”6 Witham et al. 
(2013) study used vitamin D2 (because it was the largest dose of oral vitamin D available). 
Vitamin D3 has a greater peak levels and longer half-life, therefore results in Witham et al. 
(2013) could be different if vitamin D3 was used as intervention.
2
 
 Vitamin D supplements are readily available over the counter in United States. Vitamin D 
is thought to be important for maintaining normal function of tissues such as muscle (including 
heart muscle), immune function, and inflammation.
1
 The U.S. National Academy of Science 
recommends 800 IU vitamin D/day from food and supplement.
1
 Vitamin D intoxication is rare 
but it can cause hypercalcemia.
1 
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CONCLUSION 
 The results of the RTC’s studies suggested that vitamin D does not improve the physical 
performance in the older adults with the heart failure. The cross-sectional study indicated there is 
no association between serum vitamin D levels and muscle strength. 
Future studies should be conducted with Vitamin D treatment starting at the earliest stage 
of HF to determine whether increasing Vitamin D concentration to an optimal level will prevent 
progression of HF and manifestation of physical functioning decline. In addition further studies 
should be conducted with lower doses and more frequent doses of vitamin D with conjunction of 
including a larger sample size.  
Boxer et al. (2010) points out to the importance of sun-exposure in maintaining the serum 
concentration level of vitamin D.
7
 Patients with heart failure have limited mobility ability and 
therefore might be deprived from sun-exposure. Future studies are warranted to investigate the 
relation of sun-exposure to serum concentration level of vitamin D and its effect on physical 
performance in patients with heart failure. 
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